Publisher： Adis International
ISSN： 0114-9954
Source： Reactions Weekly, Vol.1, Iss.1162, 2007-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
EMEA recommends suspending Acomplia
Reactions Weekly, Vol. 1, Iss. 1226, 2008-01 ,pp. :
Access to resources
Recommend
EMEA recommends suspending Acomplia
Inpharma, Vol. 1, Iss. 1662, 2008-01 ,pp. :
Swedish MPA highlights psychiatric reactions to Acomplia
Reactions Weekly, Vol. 1, Iss. 1208, 2008-01 ,pp. :
Obesity Market Set for Take-Off - Acomplia is Leading the Way
Pharmaceutical & Diagnostic Innovation, Vol. 2, Iss. 4, 2004-09 ,pp. :
Sanofi-aventis has launched its rimonabant 20 mg/day [Acomplia] in the UK
Inpharma, Vol. 1, Iss. 1545, 2006-01 ,pp. :